Brendan Hannah's most recent trade in Quince Therapeutics Inc was a trade of 37,736 Warrants done . Disclosure was reported to the exchange on June 18, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Quince Therapeutics Inc | Brendan Hannah | CBO, COO & CCO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jun 2025 | 37,736 | 37,736 | - | - | Warrants | |
| Quince Therapeutics Inc | Brendan Hannah | CBO, COO & CCO | Grant, award, or other acquisition of securities at price $ 1.20 per share. | 18 Jun 2025 | 37,736 | 334,276 (1%) | 0% | 1.2 | 45,283 | Common Shares |
| Quince Therapeutics Inc | Brendan Hannah | CBO, COO and CCO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jan 2025 | 450,000 | 450,000 | - | - | Employee Stock Option (right to buy) | |
| Quince Therapeutics Inc | Brendan Hannah | CHIEF BUSINESS OFFICER AND COO | Purchase of securities on an exchange or from another person at price $ 0.63 per share. | 19 Aug 2024 | 23,565 | 296,540 (1%) | 0% | 0.6 | 14,846 | Common Stock |
| Quince Therapeutics Inc | Brendan Hannah | CHIEF BUSINESS OFFICER AND COO | Purchase of securities on an exchange or from another person at price $ 0.62 per share. | 19 Aug 2024 | 5,000 | 272,975 (0%) | 0% | 0.6 | 3,100 | Common Stock |
| Quince Therapeutics Inc | Brendan Hannah | CHIEF BUSINESS OFFICER AND COO | Purchase of securities on an exchange or from another person at price $ 0.60 per share. | 19 Aug 2024 | 3,424 | 265,695 (0%) | 0% | 0.6 | 2,054 | Common Stock |
| Quince Therapeutics Inc | Brendan Hannah | CHIEF BUSINESS OFFICER AND COO | Purchase of securities on an exchange or from another person at price $ 0.61 per share. | 19 Aug 2024 | 2,500 | 262,271 (0%) | 0% | 0.6 | 1,525 | Common Stock |
| Quince Therapeutics Inc | Brendan Hannah | CHIEF BUSINESS OFFICER AND COO | Purchase of securities on an exchange or from another person at price $ 0.61 per share. | 19 Aug 2024 | 2,280 | 267,975 (0%) | 0% | 0.6 | 1,391 | Common Stock |
| Quince Therapeutics Inc | Brendan Hannah | CHIEF BUSINESS OFFICER AND COO | Purchase of securities on an exchange or from another person at price $ 0.58 per share. | 19 Aug 2024 | 2,155 | 259,771 (0%) | 0% | 0.6 | 1,250 | Common Stock |
| Quince Therapeutics Inc | Brendan Hannah | CHIEF BUSINESS OFFICER AND COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Jun 2024 | 56,061 | 47,439 | - | - | Employee Stock Option (right to buy) | |
| Quince Therapeutics Inc | Brendan Hannah | CHIEF BUSINESS OFFICER AND COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.55 per share. | 04 Jun 2024 | 56,061 | 257,616 (0%) | 0% | 0.6 | 30,834 | Common Stock |
| Quince Therapeutics Inc | Brendan Hannah | CHIEF BUSINESS OFFICER AND COO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2024 | 600,000 | 600,000 | - | - | Employee Stock Option (right to buy) | |
| Quince Therapeutics Inc | Brendan Hannah | Chief Business Officer | Purchase of securities on an exchange or from another person at price $ 1.22 per share. | 08 Aug 2023 | 71,762 | 201,555 (0%) | 0% | 1.2 | 87,550 | Common Stock |
| Quince Therapeutics Inc | Brendan Hannah | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2023 | 225,000 | 225,000 | - | - | Employee Stock Option (right to buy) | |
| Quince Therapeutics Inc | Brendan Hannah | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 May 2022 | 113,569 | 129,793 (0%) | 0% | 0 | Common Stock |